Pharmaceutical giant Sanofi ends development of Covid messenger-RNA vaccine

The pharmaceutical giant, which has lagged rivals in deploying technology behind some of the world's top-selling Covid shots, made the decision despite positive results in phase one and two trials

Sanofi doesn’t plan to pursue the development of a messenger RNA vaccine against Covid-19 because the shot will come too late to market.

The French pharmaceutical giant, which has lagged rivals in deploying the technology behind some of the world’s top-selling Covid shots, made the decision despite positive results in phase one and two trials. 

Carrying on with the development wouldn’t address an immediate public health need, because the product would arrive too late on the market, Thomas Triomphe, head of Sanofi’s vaccine unit, said at a press conference in Paris. Sanofi instead is focusing on another vaccine based on recombinant protein